Lifeline in €6.2m round for Tilt Biotherapeutics

The funding includes €4.5m in equity, which features a €500,000 convertible loan and a long-term government loan of up to €1.7m from Business Finland. 

The company has so far raised €18m in funding from Lifeline, Finnish private investors, the European Innovation Council, and Business Finland. 

The biotech company will use the proceeds from the latest fundraising to advance its proprietary products into phase-I clinical trials in Europe and the US, prepare for phase-II trials, as well as use the capital to scale up manufacturing. 

Tilt has also appointed Kenneth Forssell and Pekka Mattila to its board of directors, and Jyrki Liljeroos to an advisory role for the board of directors. 

Company
Founded in 2013 and based in Helsinki, Tilt is a  is biotechnology, clinical-stage company developing cancer immunotherapies. According to its LinkedIn page, it employs 11-50 staff. 

People
Tilt Biotherapeutics – Akseli Hemminki (CEO).
Business Finland – Minna Hendolin (senior director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• Finland
• Nordic venture
• Nordic healthcare